Document Title: PCT Doc Ref.: Version No.: 1/2014. Local Doc Ref.:

Size: px
Start display at page:

Download "Document Title: PCT Doc Ref.: Version No.: 1/2014. Local Doc Ref.:"

Transcription

1 Document Title: Patient Group Direction (PGD) for the vaccination of pregnant women (gestation week 28 onwards) and new mothers against pertussis (Whooping Cough) using Boostrix-IPV (Diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content) (dtap/ipv)) PCT Doc Ref.: Local Doc Ref.: PGD Version No.: 1/2014 Owner: File Reference: Document Overseeing Group: Placement in Framework: Jayne Carter, Administrator for Public Health Direct Commissioning Team I:\AngleseyHouse\Commissioning Directorate\Primary Care & Specialised Commissioning\Public Health\Immunisation\ \PGDs\Approved Approval Level: Date of Approval: PGD Oversight and Authorisation Group June 2014 Review Date: June 2016 Amendment Dates: Page(s) Brief Description June 2014 Boostrix-IPV PGD for the vaccination of pregnant women against pertussis developed in response to national change in pertussis vaccine procurement 1. This PGD will come into effect on 1 st July and will replace Repevax PGD for the vaccination of pregnant women against pertussis. Start date: 1 July 2014; Expiry date: 30 June 2016 Page 1 of 10

2 Patient Group Direction (PGD) for the vaccination of pregnant women (gestation week 28 onwards) and new mothers against pertussis (Whooping Cough) using Boostrix-IPV (Diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content) (dtap/ipv)) For use during temporary programme of pertussis (Whooping Cough) vaccination of Pregnant Women Approved By NHS England Shropshire and Staffordshire Area Team Name Signature Medical Director Dr Ken Deacon Head of Public Health and Primary Care Mrs Rebecca Woods LPN Pharmacy Chair Dr Manir Hussain Date of patient group direction approved Date this patient group direction becomes due for review 30 June June 2016 or in response to new local/national guidelines. Start date: 1 July 2014; Expiry date: 30 June 2016 Page 2 of 10

3 STAFF CHARACTERISTICS Provider of NHS services within Shropshire and Staffordshire Area Team geography Registered nurse with current NMC registration Specialist competencies or qualifications: The clinical manager/ lead GP has evidence that the health care professional has undertaken training to carry out clinical assessment of patient leading to confirmation that the patient requires treatment according to the indications listed in the PGD. The healthcare professional must provide evidence of training, appropriate annual updates and continued professional development undertaken to support their competence for administration of this treatment. The clinical manager /lead GP has proof of training by the healthcare professional on the legal aspects of supply or administration of medicines under a Patient Group Direction The clinical manager/ lead GP has assessed the competency of the healthcare professional to work to this Patient Group Direction. The healthcare professional has undertaken training and annual updates in the recognition and treatment of anaphylaxis, including practical in Basic Life Support and has immediate access to an in-date supply of adrenaline 1mg in 1ml (1:1000) at the time of the consultation. (The practitioner must be deemed competent in basic life support and in emergency administration of adrenaline) The health care professional must have access to all relevant sources of information e.g. information issued by the Department of Health (Green Book), British National Formulary (BNF), Summary of Product Characteristics (SPC), and the clinical guideline concerning medicine(s) within this Patient Group Direction (PGD). The practitioner must be competent and knowledgeable in vaccine cold chain standards. The practitioner needs to reinforce and update their knowledge and skills in this area of practice with particular reference to changes and national directives The registered healthcare practitioner is professionally accountable for supply or administration under the PGD as defined in their own profession s Code of Professional Conduct and Ethics. YOU MUST BE AUTHORISED BY NAME BY YOUR MANAGER UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT PGDs DO NOT REMOVE INHERENT PROFESSIONAL OBLIGATIONS OR ACCOUNTABILITY Start date: 1 July 2014; Expiry date: 30 June 2016 Page 3 of 10

4 CLINICAL CONDITION Clinical need addressed Inclusion criteria There has been a considerable increase in pertussis activity in the UK since mid The current national outbreak is the largest seen in the UK for over a decade. The greatest number of cases is in infants under the age of 3 months 3. The purpose of the programme is to boost antibodies in the vaccinated women in late pregnancy, so that pertussis specific antibodies are passed from the mother to her baby. The aim is to protect the infant before routine immunisation can be started at 8 weeks of age 3. Boostrix-IPV vaccine (dtap/ipv) should be offered to:- Pregnant women, in the period weeks 28 to 38 (inclusive) of pregnancy; the optimal time is in the period weeks 28 to 32 (inclusive) 3,4,5. Pregnant women who are now beyond week 38 of pregnancy should be offered immunisation up to the onset of labour so that some direct protection may still be provided to the infant 4,5 New mothers who have never previously been vaccinated against pertussis, up to when their child receives their first vaccination (usually at 8 weeks of age) 4,5. NB: There is no evidence of risk from vaccinating pregnant women or those who are breast-feeding with inactivated viral or bacterial vaccines or toxoids (Plotkin and Orenstein, 2004) 6,. NB: Women who have had the pertussis infection itself should still receive the vaccination as protection gained from natural infection is not life long and wanes over time. Vaccination will provide optimal antibody levels for the pregnant women to pass to her baby Exclusion criteria (for full details of interacting medicines refer to current Summary of Product Characteristics (SPC) & BNF) Pregnant women under 28 weeks of pregnancy Non consenting pregnant women There are very few medical reasons why Boostrix-IPV should not be given, however it should not be given to pregnant women who have had:- A confirmed anaphylactic reaction to a previous dose of pertussis, diphtheria, tetanus or polio vaccines; 7 A confirmed anaphylactic reaction to any component of the vaccine or to any substances carried over from manufacture including neomycin or polymyxin. 7 Confirmed anaphylactic reaction to latex. Manufacturer (GSK) should be contacted to determine the latex content of the batch of vaccine to be used 7 An encephalopathy (brain disorder) of unknown origin within seven days of previous immunisation with pertussis-containing vaccine 7 Transient thrombocytopenia or neurological complications following an Start date: 1 July 2014; Expiry date: 30 June 2016 Page 4 of 10

5 earlier immunisation against diphtheria and/or tetanus. 7 Temporary Exclusion If the pregnant woman is acutely unwell and has a fever, immunisation should be postponed until she has recovered. This is to avoid wrongly associating any cause of fever, or its progression, with the vaccine and to avoid increasing any pre-existing fever. Having a minor illness without a fever (e.g. a cold) is not a reason to delay immunisation. 6 Caution/need for further advice NB: The use of Boostrix-IPV is NOT contraindicated for breast feeding mothers. 7 Egg allergy is NOT a contraindication A history or a family history of convulsions and a family history of an adverse event following DTP vaccination DO NOT constitute contraindications 7 If any of the following events are known to have occurred around the time of receipt of a previous pertussis-containing vaccine, the decision to give pertussis-containing vaccines should be carefully considered 7 : - Temperature of 40.0 C within 48 hours of vaccination, not due to another identifiable cause. - Collapse or shock-like state (hypotonic-hyporesponsiveness episode) within 48 hours of vaccination. - Convulsions with or without fever, occurring within 3 days of vaccination. Vaccination should be deferred for individuals with evidence of current neurological deterioration including poorly controlled epilepsy 6,. Boostrix-IPV should be administered with caution to patients with thrombocytopenia or a bleeding disorder since bleeding may occur following an intramuscular administration 7 (see Route/Method section below) Interaction with other medicinal products Concomitant administration of Boostrix-IPV and other vaccines or with immunoglobulins has not been studied. It is unlikely that co-administration will result in interference with the immune responses 7. As with other vaccines, patients receiving immunosuppressive therapy may not achieve an adequate response 7. Boostrix-IPV may be administered concomitantly with human papilloma virus vaccine with no clinically relevant interference with antibody response to any of the components of either vaccine 7. According to generally accepted vaccine practices and recommendations, if concomitant administration of Boostrix-IPV with other vaccines or immunoglobulins is considered necessary, they should be given at separate sites preferably in a different limb. If given in the same limb they should be at least 2.5cm apart 6,7 There are no reasons why Boostrix-IPV cannot be administered at the same time as influenza vaccine. However, influenza immunisation should not be delayed until week 28 of the pregnancy, or after, in order to give Boostrix- Start date: 1 July 2014; Expiry date: 30 June 2016 Page 5 of 10

6 Management of excluded patients Action for patients not wishing to receive care under this PGD IPV at the same visit. Pregnant women are at risk of severe illness at any stage of pregnancy from influenza. 8 Document in the individual s notes, advise and counsel accordingly. Specialist advice must be sought on the vaccines and circumstances under which they should be given. The risk to the individual of not being immunised must be taken into account For individuals temporarily excluded due to acute or febrile illness advise when the vaccine may be given and arrange another appointment. Give advice about protective effects of the vaccine and the risks of infection and disease complications. Document advice given. Inform or refer to GP as appropriate. TREATMENT AND DRUG DETAILS Name form and strength of medicine Boostrix-IPV (Diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content) (dtap/ipv)) Legal classification Boostrix-IPV is a sterile turbid white suspension supplied in a single dose (0.5 ml) pre-filled syringe. POM Prescription Only Medicine Black triangle warning Suspected adverse reactions. Should be reported using the Yellow Card reporting scheme (http://yellowcard.mhra.gov.uk). Method of obtaining supply Site for treatment Route/method Dose Not applicable GP practices will be able to order Boostrix-IPV through ImmForm as part of this programme. GP surgeries Boostrix-IPV should be administered by deep intramuscular injection preferably into the deltoid muscle. 7 Intramuscular injections should be given with care in patients on anticoagulant therapy or suffering from coagulation disorders because of the risk of haemorrhage. In these situations and following official recommendations the administration of Boostrix-IPV by deep subcutaneous injection may be considered, although there is a risk of increased local reactions ml maximum dose 0.5 ml A single 0.5ml dose of Boostrix-IPV should be given irrespective of the number of foetuses in the pregnancy 3 Number of times treatment may be administered N.B. Shake vaccine gently immediately before administration to obtain a homogeneous turbid white suspension. Prior to administration, the vaccine should be visually inspected for any foreign particulate matter and/or variation of physical aspect. In the event of either being observed, discard the vaccine. Women who become pregnant again while the programme is in place should be offered immunisation during each pregnancy to maximise transplacental transfer of antibody. Pregnant women who have received Start date: 1 July 2014; Expiry date: 30 June 2016 Page 6 of 10

7 Quantity to be supplied or administered Side effects Full details of side effects are available in the SPC. Suspected adverse reactions to drugs including vaccines should be reported on the yellow card available at the back of the BNF. Also at immunisation against pertussis, tetanus, diphtheria and/or polio relatively recently should also be offered immunisation, but with a gap of at least one month between immunisations. Although cumulative doses may increase the likelihood of injection site reactions or fever, this is outweighed by the expected benefit to the infant. 3 Single dose to be administered (0.5ml) 7 Inform the patient about possible side effects and their management. Give advice on temperature control Adverse Effects 7 Very common ( 1/10) Common ( 1/100 to <1/10) (in subjects aged 10 to 93 years) System Organ Class Frequency Adolescents and Adults Nervous System Disorders Very common Headache Gastrointestinal Disorders Common Vomiting, abdominal pain, nausea Additional Information (including storage and disposal) General Disorders and Administration Site Conditions Very common Common Injection site reactions (such as redness and/or swelling), fatigue, injection site pain Pyrexia (fever 37.5 C), injection site reactions (such as haematoma, pruritus, induration and warmth numbness) For further details about adverse effects see product SPC Store in a refrigerator (2 0 C 8 0 C) Do not freeze (If the vaccine has been frozen, the vaccine should be discarded) Protect from light (store in original packaging) Upon removal from refrigerator the vaccine is stable for 8 hours at 21 0 C Equipment used for vaccination, including used vials, ampoules, nasal applicator or partially discharged vaccines should be disposed of at the end of a session by sealing in a proper, puncture-resistant sharps box according to local authority regulations and guidance in the technical memorandum (Department of Health, 2006). i Boostrix-IPV is thiomersal free Advice to patient/carer Before Treatment: Advise patient of possible side effects. For full details see product s Start date: 1 July 2014; Expiry date: 30 June 2016 Page 7 of 10

8 summary of product characteristics. Advise action to be taken if side effects are experienced After Treatment: Provide patient information leaflet Any serious adverse reaction to the vaccine should be documented in the patient s GP medical records and the MHRA should be informed using the yellow card scheme. GP should also be informed. Follow up Suspected adverse reactions No routine follow up required Patient presenting with suspected adverse drug reaction should be referred to a doctor for further investigations. As with all vaccines, healthcare professionals and parents/carers are encouraged to report suspected adverse reactions to the Medicines and Healthcare products Regulatory Agency (MHRA) using the Yellow Card reporting scheme on: Error reporting RECORD KEEPING Documentation needed/treatment records to be kept for audit purposes A computer or manual record of all individuals receiving treatment under this Patient Group Direction should also be kept for audit purposes. Any serious adverse reaction to the vaccine should be documented in the patient s medical record. Any incidents or near-miss issues must be reported to the Area Team immunisations query line: Patient s name, address, date of birth and registered GP Manufacturer/brand of product, batch number, expiry date Record of informed consent Dose administered Date of administration Anatomical site of vaccination Route of administration Advice given to patient (including advice given if vaccination is declined) Details of staff who administered (sign and print name) Details of any adverse drug reactions, and action taken including informing GP Record as supplied via Patient Group Direction (PGD) in patient s clinical record All records should be clear, legible and contemporaneous. This information should be recorded as appropriate in the patient s General Practitioner record or other patient record. A computerised or manual record of all individuals receiving treatment under this Patient Group Direction should also be kept for audit purposes. Clinical records must be kept for at least 8 years following completion of treatment. In patients who are aged under 17 years, clinical records must be kept until the patient s 25th birthday. Data must be stored in accordance with Caldicott guidance and the Data Protection Act. Start date: 1 July 2014; Expiry date: 30 June 2016 Page 8 of 10

9 Reconciliation stock balances should be reconcilable with receipts, administration records and disposal. Register of practitioners qualified to administer and/or supply Boostrix-IPV (Diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content) (dtap/ipv)) under this Patient Group Direction Name of clinical manager/gp Lead Signature of clinical manager/gp Date: Lead A copy of this page should be retained by the authorising manager for 2 years for audit purposes Please state clinical area where this PGD is in use Healthcare professional individual declaration I have read and understood the Patient Group Direction and agree to supply this medicine only in accordance with this PGD PGDs DO NOT REMOVE INHERENT PROFESSIONAL OBLIGATIONS OR ACCOUNTABILITY. It is the responsibility of each professional to practice only within the bounds of their own competence. All practitioners operating in accordance with this PGD should have a current, signed copy of it readily available for reference. If a practitioner is asked to supply, or administer a medicine not covered by this or any other PGD then a patient specific direction is required from a doctor, dentist or independent prescriber. Name of professional (please print) Signature Authorising Manager (Must sign against each entry) Date of authorisation The clinical lead should review competency of authorised practitioners annually. Authorisation to use this PGD does not remove inherent professional responsibility and accountability References 1 Public Health England. Vaccine update issue 213 March Public Health England Vaccine update issue 215 May CMO letter 27 th September Gateway reference: Start date: 1 July 2014; Expiry date: 30 June 2016 Page 9 of 10

10 4 Deputy NHS Chief Executive Letter 28 th September Gateway reference number: Public Health England Letter 10 th May Continuation of temporary programme of pertussis (whooping cough) vaccination of pregnant women. 6 Green Book DOH (2006) Immunisation against Infectious Disease: London: HMSO (Chapter 24 Pertussis) 7 Boostrix-IPV Product SPC 8 Health Protection Scotland. NHS National Services Scotland, NHS Education for Scotland Vaccination against pertussis (whooping cough) the replacement of Repevax with Boostrix-IPV An update for registered healthcare practitioners May 2014 Start date: 1 July 2014; Expiry date: 30 June 2016 Page 10 of 10

Vaccination against pertussis (whooping cough) - the replacement of Repevax with Boostrix -IPV an update for registered healthcare practitioners

Vaccination against pertussis (whooping cough) - the replacement of Repevax with Boostrix -IPV an update for registered healthcare practitioners Vaccination against pertussis (whooping cough) - the replacement of Repevax with Boostrix -IPV an update for registered healthcare practitioners Questions and Answers May 2014 Health Protection Scotland

More information

Vaccination against pertussis (Whooping cough) for pregnant women- 2014. Information for healthcare professionals

Vaccination against pertussis (Whooping cough) for pregnant women- 2014. Information for healthcare professionals Vaccination against pertussis (Whooping cough) for pregnant women- 2014 Information for healthcare professionals About Public Health England Public Health England s mission is to protect and improve the

More information

Factsheet September 2012. Pertussis immunisation for pregnant women. Introduction

Factsheet September 2012. Pertussis immunisation for pregnant women. Introduction Factsheet September 2012 Pertussis immunisation for pregnant women Introduction The routine childhood immunisation programme has been very effective in reducing the overall numbers of cases of pertussis.

More information

Pertussis (whooping cough) immunisation for pregnant women the safest way to protect yourself and your baby

Pertussis (whooping cough) immunisation for pregnant women the safest way to protect yourself and your baby Factsheet September 2012 Pertussis (whooping cough) immunisation for pregnant women the safest way to protect yourself and your baby The routine childhood immunisation programme has been very effective

More information

Pertussis (whooping cough) immunisation for pregnant women

Pertussis (whooping cough) immunisation for pregnant women Factsheet September 2012 Pertussis (whooping cough) immunisation for pregnant women Immunisation DEPARTMENT OF HEALTH Rheynn Slaynt The routine childhood immunisation programme has been very effective

More information

TEMPORARY PROGRAMME PERTUSSIS VACCINATION FOR PREGNANT WOMEN

TEMPORARY PROGRAMME PERTUSSIS VACCINATION FOR PREGNANT WOMEN TEMPORARY PROGRAMME PERTUSSIS VACCINATION FOR PREGNANT WOMEN Richard Smithson Neil Irvine Maureen McCartney Consultant Health Protection October 2012 Pertussis/whooping cough The disease Whooping Cough

More information

Document Title: Patient Group Direction for Adrenaline (Epinephrine) 1:1000. http://www.england.nhs.uk/mids-east/ss-at/immunisations/

Document Title: Patient Group Direction for Adrenaline (Epinephrine) 1:1000. http://www.england.nhs.uk/mids-east/ss-at/immunisations/ Document Title: Patient Group Direction for Adrenaline (Epinephrine) 1:1000 Area Team Doc Ref.: PGD Version No.: 06/2014 Doc Ref.: Author: Owner: File Reference: Document Overseeing Group: http://www.england.nhs.uk/mids-east/ss-at/immunisations/

More information

The clinical studies have been performed in children, adolescents and adults, from 4 years up to 55 years of age.

The clinical studies have been performed in children, adolescents and adults, from 4 years up to 55 years of age. NAME OF THE MEDICINE TdaP-Booster. Diphtheria, tetanus and pertussis (acellular mono-component) vaccine (adsorbed, reduced antigen content). DESCRIPTION TdaP-Booster is a suspension for injection in pre-filled

More information

TdaP-Booster (tee-dee-ay-pee boo-ster)

TdaP-Booster (tee-dee-ay-pee boo-ster) New Zealand Consumer Medicine Information TdaP-Booster (tee-dee-ay-pee boo-ster) Tetanus, diphtheria and pertussis (acellular mono-component) vaccine (adsorbed, reduced antigen content) CONSUMER MEDICINE

More information

Vaccination against pertussis (Whooping cough) for pregnant women Information for healthcare professionals

Vaccination against pertussis (Whooping cough) for pregnant women Information for healthcare professionals Vaccination against pertussis (Whooping cough) for pregnant women- 2016 Information for healthcare professionals About Public Health England Public Health England exists to protect and improve the nation's

More information

Patient Group Direction PGD No /15 Administration of Human Papillomavirus Vaccine (HPV) Types 6, 11, 16 and 18 - Gardasil

Patient Group Direction PGD No /15 Administration of Human Papillomavirus Vaccine (HPV) Types 6, 11, 16 and 18 - Gardasil Notice to all staff: This Patient Group Direction (PGD) may only be used by members of the healthcare professions named on the title page, and only if each professional has individually been listed by

More information

Unit Operational Managers

Unit Operational Managers Title: Patient Group Direction for the administration of DTaP/IPV/Hib (Pediacel ) by nurses working within NHS Grampian Identifier: Replaces: Across NHS Boards NHSG/PGD/pediacel/MGPG536 NHSG/PGD/pediacel/MGPG370

More information

Consultation Group: See relevant page in the PGD. Review Date: July 2016

Consultation Group: See relevant page in the PGD. Review Date: July 2016 Patient Group Direction For The Administration Of Gardasil Vaccine Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, Adsorbed) By Nurses, Midwives and Health Visitors Working Within NHS

More information

Enhanced Service Specification. Pertussis (pregnant women) vaccination programme 2015/16

Enhanced Service Specification. Pertussis (pregnant women) vaccination programme 2015/16 Enhanced Service Specification Pertussis (pregnant women) vaccination programme 2015/16 NHS England INFORMATION READER BOX Directorate Medical Commissioning Operations Patients and Information Nursing

More information

Patient Group Direction For The Administration Of Rotavirus Vaccine Rotarix By Nurses, Midwives and Health Visitors Working Within NHS Grampian

Patient Group Direction For The Administration Of Rotavirus Vaccine Rotarix By Nurses, Midwives and Health Visitors Working Within NHS Grampian Patient Group Direction For The Administration Of Rotavirus Vaccine Rotarix By Nurses, Midwives and Health Visitors Working Within NHS Grampian Co-ordinators: Adapted from National PGD See Page 1 Consultation

More information

Chapter 8. Vaccine Administration

Chapter 8. Vaccine Administration Chapter 8 Vaccine Administration 8.1 Objectives To understand how to prepare vaccines for immunisation To understand how to administer vaccines To understand what are true contraindications for vaccine

More information

Whooping Cough Vaccine for Pregnant Women

Whooping Cough Vaccine for Pregnant Women Whooping Cough Vaccine for Pregnant Women What is whooping cough (pertussis)? Whooping cough (also known as pertussis) is a highly contagious illness that can be life threatening. The disease is most serious

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS Registration No. : 2C 22/47 (N) Importer / Manufacturer: Sanofi Pasteur Ltd., Thailand/Sanofi Pasteur S.A., France SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICAL PRODUCT : PENTAXIM (Diphtheria,

More information

Clinical Performance Director of Nursing Allison Bussey

Clinical Performance Director of Nursing Allison Bussey PGD 0314 Patient Group Direction Administration of Adrenaline (Epinephrine) 1:1000 (1mg/ml) Injection By Registered Nurses employed by South Staffordshire & Shropshire Healthcare Foundation NHS Trust This

More information

BE SURE. BE SAFE. VACCINATE.

BE SURE. BE SAFE. VACCINATE. DON T GET OR GIVE THE FLU THIS YEAR THANK YOU Vaccination is the only protection. www.immunisation.ie BE SURE. BE SAFE. VACCINATE. FLU VACCINE 2013-2014 Healthcare workers prevent the spread of flu and

More information

NHSG/PGD/lido_eton/MGPG412 Organisation Wide

NHSG/PGD/lido_eton/MGPG412 Organisation Wide Title: Patient Group Direction For The Administration Of Lidocaine 2% Injection For The Insertion/Removal Of The 68mg Etonogestrel Contraceptive Implant By Nurses And Midwives Working Within NHS Grampian

More information

4-in-1 & MMR vaccines

4-in-1 & MMR vaccines 4-in-1 & MMR vaccines Information for parents of children in Junior Infants www.immunisation.ie Your CHILD needs to be protected from infectious diseases when they start SCHOOL. Read this leaflet to find

More information

NATIONAL PATIENT GROUP DIRECTION FOR SUPPLY OF PARACETAMOL ORAL SUSPENSION

NATIONAL PATIENT GROUP DIRECTION FOR SUPPLY OF PARACETAMOL ORAL SUSPENSION NATIONAL PATIENT GROUP DIRECTION FOR SUPPLY OF PARACETAMOL ORAL SUSPENSION 120 mg/5ml FOR PREVENTION OF POST IMMUNISATION FEVER FOLLOWING ADMINISTRATION OF MENINGOCOCCAL GROUP B VACCINE (BEXSERO ) BY AUTHORISED

More information

Vaccinations and Spina Bifida and Hydrocephalus

Vaccinations and Spina Bifida and Hydrocephalus shinecharity.org.uk info@shinecharity.org.uk 42 Park Road Peterborough PE1 2UQ 01733 555988 Vaccinations and Spina Bifida and Hydrocephalus Vaccines are made from parts of bacteria or viruses that cause

More information

Emergency Treatment of an Anaphylactic Reaction in the Community Protocol

Emergency Treatment of an Anaphylactic Reaction in the Community Protocol Emergency Treatment of an Anaphylactic Reaction in the Community Protocol Reference Number: NHSCT/09/216 Responsible Directorate: Children s Services Replaces (if appropriate): Northern Trust Departmental

More information

Patient Group Direction Hospital: Bristol Royal Infirmary Department: UHBristol Thrombosis Service University Hospitals Bristol NHS Foundation Trust.

Patient Group Direction Hospital: Bristol Royal Infirmary Department: UHBristol Thrombosis Service University Hospitals Bristol NHS Foundation Trust. Patient Group Direction Hospital: Bristol Royal Infirmary Department: UHBristol Thrombosis Service University Hospitals Bristol NHS Foundation Trust. This Patient Group Direction (PGD) has been written

More information

Whooping cough and pregnancy

Whooping cough and pregnancy Whooping cough and pregnancy Your questions answered on how to help protect your baby 2014 edition the safest way to protect yourself and your baby 1 There is a lot of whooping cough around at the moment

More information

Patient Group Direction for the Administration of Hepatitis B vaccine

Patient Group Direction for the Administration of Hepatitis B vaccine Patient Group Direction for the Administration of Hepatitis B vaccine This PGD must be read in conjunction with the core PGD (Reference: NHSE(LR)/PGD/Core PGD for Immunisations), which details information

More information

Tdap booster vaccine for Health Care Workers Frequently Asked Questions for Health Professionals

Tdap booster vaccine for Health Care Workers Frequently Asked Questions for Health Professionals Tdap booster vaccine for Health Care Workers Frequently Asked Questions for Health Professionals NEW items in 2013 Immunisation Guidelines for Ireland are in RED What is Tdap booster vaccine? Tdap is a

More information

Women, Children s and Sexual Health Division Maternity Services. MMR / Rubella Vaccine for Postnatal Woman

Women, Children s and Sexual Health Division Maternity Services. MMR / Rubella Vaccine for Postnatal Woman Women, Children s and Sexual Health Division Maternity Services Guideline: MMR - Rubella Vaccination for Postnatal Woman 1. Introduction Rubella vaccine is usually given in childhood along with the measles

More information

Patient Group Directions. Guidance and information for nurses

Patient Group Directions. Guidance and information for nurses Patient Group Directions Guidance and information for nurses Patient Group Directions Guidance and information for nurses Contents Introduction 4 What is a patient group direction (PGD)? 4 When can PGDs

More information

IMPORTANT: PLEASE READ

IMPORTANT: PLEASE READ PART III: CONSUMER INFORMATION combined hepatitis A (inactivated) and hepatitis B (recombinant) vaccine This leaflet is part III of a three-part "Product Monograph" published when was approved for sale

More information

Tdap and MenC booster vaccines. Information for parents of children in First Year of second level school

Tdap and MenC booster vaccines. Information for parents of children in First Year of second level school Tdap and MenC booster vaccines Information for parents of children in First Year of second level school Tdap and MenC booster vaccines Information for parents of children in First Year of second level

More information

Vaccination is the only protection. BE SURE. BE SAFE. VACCINATE.

Vaccination is the only protection.  BE SURE. BE SAFE. VACCINATE. Vaccination is the only protection. www.immunisation.ie BE SURE. BE SAFE. VACCINATE. FLU VACCINE 2011-2012 INFORMATION FOR PREGNANT WOMEN What is seasonal flu (influenza)? Seasonal flu is a highly infectious

More information

Children & Young People s Directorate. School Nursing Procedure For Administration of Immunisations

Children & Young People s Directorate. School Nursing Procedure For Administration of Immunisations Children & Young People s Directorate School Nursing Procedure For Administration of Immunisations Author Mrs Gladys Bleakley & Mrs Barbara Ervine Directorate responsible for Children & Young Peoples this

More information

MENINGOCOCCAL GROUP B VACCINE (BEXSERO) Information for Health Professionals

MENINGOCOCCAL GROUP B VACCINE (BEXSERO) Information for Health Professionals MENINGOCOCCAL GROUP B VACCINE (BEXSERO) Information for Health Professionals What is Bexsero vaccine? Bexsero is a meningococcal Group B (MenB) vaccine which is indicated for the active immunisation of

More information

Polio and the Introduction of IPV

Polio and the Introduction of IPV Polio and the Introduction of IPV Poliomyelitis (polio) is a highly infectious disease that is caused when a person is infected by the polio virus that invades the nervous system. Poliomyelitis can cause

More information

FREQUENTLY ASKED QUESTIONS ABOUT PERTUSSIS (WHOOPING COUGH)

FREQUENTLY ASKED QUESTIONS ABOUT PERTUSSIS (WHOOPING COUGH) FREQUENTLY ASKED QUESTIONS ABOUT PERTUSSIS (WHOOPING COUGH) What is pertussis? General Questions About Pertussis Pertussis, or whooping cough, is a contagious illness that is spread when an infected person

More information

The Kroger Pharmacy Vaccine Administration Training Program Self-Study Quiz

The Kroger Pharmacy Vaccine Administration Training Program Self-Study Quiz The Kroger Pharmacy Vaccine Administration Training Program Self-Study Quiz Name: Date: Score: Please darken the letter on the Answer Sheet (last page) that corresponds to the correct answer, and bring

More information

Medicines Management

Medicines Management Medicines Management Patient Group Direction for the Supply/administration of Adrenaline (Epinephrine) for Treatment of Anaphylaxis by accredited community Pharmacists. Rationale To enable a pharmacist,

More information

National Chlamydia Screening Programme September 2012 PATIENT GROUP DIRECTION FOR THE ADMINISTRATION OF AZITHROMYCIN FOR CHLAMYDIA TRACHOMATIS

National Chlamydia Screening Programme September 2012 PATIENT GROUP DIRECTION FOR THE ADMINISTRATION OF AZITHROMYCIN FOR CHLAMYDIA TRACHOMATIS PATIENT GROUP DIRECTION FOR THE ADMINISTRATION OF AZITHROMYCIN FOR CHLAMYDIA TRACHOMATIS Below is a template that can be used to produce a local patient group direction (PGD) for the administration of

More information

Parents and Grandparents

Parents and Grandparents Parents and Grandparents Vaccination for parents and grandparents is vital to help protect newborn babies against whooping cough. Protect your baby by being immunised too. To find out more about Boostrix

More information

Developed / Reviewed by the Collaborative Provider PGD (Patient Group Direction) Group (CPPGDG) and approved by the following members of the CPPGDG:

Developed / Reviewed by the Collaborative Provider PGD (Patient Group Direction) Group (CPPGDG) and approved by the following members of the CPPGDG: Patient Group Direction 7.02 version 4.0 Administration of Intravenous Adrenaline (Epinephrine) 1 in 10,000 (100micrograms per ml) Injection in Cardiopulmonary by Registered Practitioners in Torbay and

More information

2 months Diptheria; Tetanus; Whooping Cough; Hib & Polio 1st dose Pneumococcal Conjugate Vaccination

2 months Diptheria; Tetanus; Whooping Cough; Hib & Polio 1st dose Pneumococcal Conjugate Vaccination IMMUNISATIONS You may want to know if your child should have routine immunisations and whether there could be an increased risk of complications because of the heart condition. We have sought the opinions

More information

NHS FORTH VALLEY. Administration of VZIG in close contact with chicken pox or shingles in a pregnant woman. Unit Clinical Governance

NHS FORTH VALLEY. Administration of VZIG in close contact with chicken pox or shingles in a pregnant woman. Unit Clinical Governance NHS FORTH VALLEY Date of First Issue 01/04/2006 Approved 05/05/2012 Current Issue Date 18/09/2012 Review Date 18/09/2016 Version 1.2 EQIA Yes 01/04/2012 Author / Contact Group Committee Final Approval

More information

Yes This controlled document shall not be copied in part or whole without the express permission of the author or the author s representative.

Yes This controlled document shall not be copied in part or whole without the express permission of the author or the author s representative. Title: Patient Group Direction for the administration of lidocaine hydrochloride 1% injection as infiltration anaesthesia for insertion/removal of central venous catheters by nurses/radiographers working

More information

ALBERTA IMMUNIZATION POLICY GUIDELINES

ALBERTA IMMUNIZATION POLICY GUIDELINES ALBERTA IMMUNIZATION POLICY GUIDELINES Diphtheria, Tetanus, Pertussis, Polio and Hib Vaccines. Diphtheria-Tetanus-Acellular Pertussis-Polio-Haemophilus influenzae type b Conjugate Combined Vaccine (DTaP-IPV-

More information

Anaphylaxis and other adverse events

Anaphylaxis and other adverse events Anaphylaxis and other adverse events Aim: To be able to manage anaphylaxis and other adverse events correctly Learning outcomes Define local and systemic adverse events Distinguish between anaphylaxis

More information

Why Pertussis matters..

Why Pertussis matters.. Why Pertussis matters.. Pertussis (Whooping cough) outbreaks continue to impact children & adults, both locally and across the US. Cases have been on the rise since the 1980 s. However, recent data on

More information

If you have any concerns about being given this vaccine, ask your doctor or pharmacist.

If you have any concerns about being given this vaccine, ask your doctor or pharmacist. PNEUMOVAX 23 Pneumococcal Vaccine Single Dose Vial/Pre-filled Syringe What is in this leaflet This leaflet answers some common questions about PNEUMOVAX 23. It does not contain all the available information.

More information

BOOSTRIX PRODUCT INFORMATION

BOOSTRIX PRODUCT INFORMATION BOOSTRIX PRODUCT INFORMATION NAME OF THE MEDICINE Combined diphtheria-tetanus-acellular pertussis (dtpa) vaccine DESCRIPTION BOOSTRIX dtpa vaccine is a sterile suspension which contains diphtheria toxoid,

More information

Whooping cough. If you are pregnant you should get vaccinated to protect your baby

Whooping cough. If you are pregnant you should get vaccinated to protect your baby Whooping cough If you are pregnant you should get vaccinated to protect your baby Cases of whooping cough are on the increase by getting the vaccine while pregnant you can protect your baby In the last

More information

Whooping cough and pregnancy

Whooping cough and pregnancy Your guide to Vaccinations Whooping cough and pregnancy What you need to know and do to help protect your baby There is a lot of whooping cough around at the moment and babies who are too young to start

More information

Whooping cough and pregnancy

Whooping cough and pregnancy Whooping cough and pregnancy Your questions answered on how to help protect your baby the safest way to protect yourself and your baby There is a lot of whooping cough around at the moment and babies who

More information

2. Characteristics of staff Qualifications required. Additional requirements. Continued education & training requirements

2. Characteristics of staff Qualifications required. Additional requirements. Continued education & training requirements Patient Group Direction The supply of Azithromycin 1g as a single dose by accredited Community Pharmacists to patients in receipt of a positive test result to Chlamydia trachomatis, and treatment of their

More information

patient group direction

patient group direction DICLOFENAC v01 1/8 DICLOFENAC PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner

More information

Summary of the risk management plan (RMP) for Tritanrix HB [Diphtheria, tetanus, pertussis (whole cell) and hepatitis B (rdna) vaccine (adsorbed)]

Summary of the risk management plan (RMP) for Tritanrix HB [Diphtheria, tetanus, pertussis (whole cell) and hepatitis B (rdna) vaccine (adsorbed)] EMA/14365/2014 Summary of the risk management plan (RMP) for Tritanrix HB [Diphtheria, tetanus, pertussis (whole cell) and hepatitis B (rdna) vaccine (adsorbed)] Overview of disease epidemiology Diphtheria

More information

Influenza Vaccine Frequently Asked Questions. Influenza Control Program

Influenza Vaccine Frequently Asked Questions. Influenza Control Program Influenza Vaccine Frequently Asked Questions Influenza Control Program Influenza or the flu can be a serious contagious disease, which is spread by droplet transmission through close contact with an infected

More information

Is your family at risk for pertussis?

Is your family at risk for pertussis? Is your family at risk for pertussis? Help protect your family against a serious disease and talk to your health-care professional about adult and adolescent immunization with Adacel vaccine. Please click

More information

IMMUNIZATION REQUIREMENTS FOR SCHOOL CHILDREN

IMMUNIZATION REQUIREMENTS FOR SCHOOL CHILDREN 10-144 DEPARTMENT OF HUMAN SERVICES BUREAU OF HEALTH Chapter 261: IMMUNIZATION REQUIREMENTS FOR SCHOOL CHILDREN A joint rule with 05-071 DEPARTMENT OF EDUCATION (COMMISSIONER) Chapter 126: IMMUNIZATION

More information

I B2.4. Design of the patient information leaflet for VariQuin

I B2.4. Design of the patient information leaflet for VariQuin (English translation of official Dutch version) I B2.4. Design of the patient information leaflet for VariQuin Information for the Patient: Read this package leaflet carefully when you have some time to

More information

PATIENT GROUP DIRECTION (PGD) ADMINISTRATION OF INHALED SALBUTAMOL FOR THE EMERGENCY TREATMENT OF ACUTE ASTHMA OR COPD EXACERBATION AT HMP FORD

PATIENT GROUP DIRECTION (PGD) ADMINISTRATION OF INHALED SALBUTAMOL FOR THE EMERGENCY TREATMENT OF ACUTE ASTHMA OR COPD EXACERBATION AT HMP FORD PATIENT GROUP DIRECTION (PGD) ADMINISTRATION OF INHALED SALBUTAMOL FOR THE EMERGENCY TREATMENT OF ACUTE ASTHMA OR COPD EXACERBATION AT HMP FORD Version Number: 01HMP Patient Group Direction originally

More information

GUIDELINE. Vaccination of Health Care Workers. Version 2 December 2012. Centre for Healthcare Related Infection Surveillance and Prevention

GUIDELINE. Vaccination of Health Care Workers. Version 2 December 2012. Centre for Healthcare Related Infection Surveillance and Prevention GUIDELINE Vaccination of Health Care Workers Version 2 December 2012 Centre for Healthcare Related Infection Surveillance and Prevention Introduction This guideline provides information to support Hospital

More information

Importer / Manufacturer: MSD (THAILAND) LTD./ Merck & Co.,Inc., West Point, Pennsylvania 19486 SUMMARY OF PRODUCT CHARACTERISTICS

Importer / Manufacturer: MSD (THAILAND) LTD./ Merck & Co.,Inc., West Point, Pennsylvania 19486 SUMMARY OF PRODUCT CHARACTERISTICS Registration No. 1C 68/47(NC) Importer / Manufacturer: MSD (THAILAND) LTD./ Merck & Co.,Inc., West Point, Pennsylvania 19486 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICAL PRODUCT VARIVAX [Varicella

More information

Pre-school immunisations

Pre-school immunisations Pre-school immunisations A guide to vaccinations at three years and four months of age the safest way to protect your child The complete routine childhood immunisation programme These booklets describe

More information

Influenza Vaccine Protocol Agreement (O.C.G.A. Section 43-34-26.1)

Influenza Vaccine Protocol Agreement (O.C.G.A. Section 43-34-26.1) Influenza Vaccine Protocol Agreement (O.C.G.A. Section 43-34-26.1) This Influenza Vaccine Protocol Agreement (the "Protocol") authorizes the Georgia licensed pharmacists (the "Pharmacists") or nurses (

More information

Medication Protocol for the Administration of Inactivated Influenza Vaccine (Split Virion) BP Version 1, September 2015

Medication Protocol for the Administration of Inactivated Influenza Vaccine (Split Virion) BP Version 1, September 2015 Medication Protocol for the Administration of Inactivated Influenza Vaccine (Split Virion) BP to nurses, midwives and Healthcare Workers by registered nurses and registered midwives This medication protocol

More information

The format of this leaflet was determined by the Ministry of Health and its content was checked and approved in May 2013.

The format of this leaflet was determined by the Ministry of Health and its content was checked and approved in May 2013. The format of this leaflet was determined by the Ministry of Health and its content was checked and approved in May 2013 Havrix 720 Junior 1 NAME OF THE MEDICINAL PRODUCT Havrix 720 Junior 2 QUALITATIVE

More information

Package Leaflet: Information for the user

Package Leaflet: Information for the user Package Leaflet: Information for the user Boostrix -IPV, Suspension for injection in pre-filled syringe Diphtheria, tetanus, pertussis (acellular component) and poliomyelitis (inactivated) vaccine (adsorbed,

More information

Childhood seasonal influenza vaccination programme

Childhood seasonal influenza vaccination programme Enhanced service specification Childhood seasonal influenza vaccination programme NHS England gateway reference: 01641 Introduction 1. All GMS practices are expected to provide essential and those additional

More information

SWINE FLU VACCINATION:

SWINE FLU VACCINATION: SWINE FLU VACCINATION: information for parents of children over six months and under five years old Flu. Protect yourself and others. Contents About this leaflet......................... 3 What is swine

More information

SEASONAL INFLUENZA VACCINE INFORMATION FOR IMMUNIZATION PROVIDERS

SEASONAL INFLUENZA VACCINE INFORMATION FOR IMMUNIZATION PROVIDERS 2015-2016 SEASONAL INFLUENZA VACCINE INFORMATION FOR IMMUNIZATION PROVIDERS Office of the Chief Medical Officer of Health Communicable Disease Control Branch Immunization Program November 2015 Table of

More information

TdaPBooster. Tetanus, diphtheria and pertussis vaccination of children, adolescents and adults throughout life

TdaPBooster. Tetanus, diphtheria and pertussis vaccination of children, adolescents and adults throughout life TdaPBooster Tetanus, diphtheria and pertussis vaccination of children, adolescents and adults throughout life CONTENTS Statens Serum Institut vaccine production Pertussis in Denmark Pertussis vaccination

More information

FAQs on Influenza A (H1N1-2009) Vaccine

FAQs on Influenza A (H1N1-2009) Vaccine FAQs on Influenza A (H1N1-2009) Vaccine 1) What is Influenza A (H1N1-2009) (swine flu) 1? Influenza A (H1N1-2009), previously known as "swine flu", is a new strain of influenza virus that spreads from

More information

Vaccination Requirements for U.S. Immigration: Technical Instructions for Panel Physicians. December 14, 2009

Vaccination Requirements for U.S. Immigration: Technical Instructions for Panel Physicians. December 14, 2009 Vaccination Requirements for U.S. Immigration: Technical Instructions for Panel Physicians December 14, 2009 Table of Contents Preface... iii Significant Changes in the Vaccination Requirements... 1 Procedure

More information

Prevention of Pertussis Among Pregnant & Post Partum Women and Their Infants. Marilyn Michels RN MSN CIC Kathleen Curtis MS RN

Prevention of Pertussis Among Pregnant & Post Partum Women and Their Infants. Marilyn Michels RN MSN CIC Kathleen Curtis MS RN Prevention of Pertussis Among Pregnant & Post Partum Women and Their Infants Marilyn Michels RN MSN CIC Kathleen Curtis MS RN Pertussis and Adults Pertussis (whooping cough) a poorly controlled vaccine-preventable

More information

swine flu vaccination:

swine flu vaccination: swine flu vaccination: what you need to know Flu. Protect yourself and others. Contents What is swine flu?............... 3 About the swine flu vaccine....... 4 What else do I need to know?...... 8 What

More information

Emergency Treatment of Anaphylactic Reactions

Emergency Treatment of Anaphylactic Reactions Emergency Treatment of Anaphylactic Reactions Authorising Officer Signature Of Authorising Officer: Tom Cahill, Deputy Chief Executive Version: V3 Ratified By: HPFT Drugs and Therapeutic Committee Date

More information

Version Number: 5. Patient Group Direction originally drawn up by: Reviewed by: Patient Group direction authorised by: Medical Lead

Version Number: 5. Patient Group Direction originally drawn up by: Reviewed by: Patient Group direction authorised by: Medical Lead PATIENT GROUP DIRECTION (PGD) FOR THE SUPPLY AND/OR ADMINISTRATION OF NALOXONE HYDROCHLORIDE INJECTION BY REGISTERED NURSES WORKING IN COMMUNITY AND INPATIENT SUBSTANCE MISUSE TEAMS Version Number: 5 Patient

More information

NHS FORTH VALLEY. Varicella Care Pathway for GPs

NHS FORTH VALLEY. Varicella Care Pathway for GPs NHS FORTH VALLEY Date of First Issue 01/04/2006 Approved 05/05/2012 Current Issue Date 28/04/2014 Review Date 28/04/2016 Version 1.2 EQIA Yes 01/04/2012 Author / Contact Debbie Forbes Group Committee Unit

More information

Vaccines for a Healthy Pregnancy

Vaccines for a Healthy Pregnancy Vaccines for a Healthy Pregnancy Vaccines for a Healthy Pregnancy G ALLERY I.1 Healthy Mother and Baby I II Introduction to Tutorial About Flu and Whooping Cough III Getting Vaccinated During Pregnancy:

More information

PATIENT GROUP DIRECTION

PATIENT GROUP DIRECTION Midlands and East (Central Midlands) PATIENT GROUP DIRECTION NHS England Midlands and East (Central Midlands): for use in Leicestershire & Lincolnshire Patient Group Direction for the administration of

More information

2 P age. Babies from Birth to Age 2

2 P age. Babies from Birth to Age 2 Contents Babies from Birth to Age 2... 2 Vaccines give parents the power... 2 Vaccines are recommended throughout our lives... 3 Talk to your doctor... 3 Vaccines are very safe... 3 Whooping Cough (Pertussis)...

More information

Donepezil (Aricept ), Galantamine (Reminyl XL ), Rivastigmine (Exelon ) and Memantine (Ebixa )

Donepezil (Aricept ), Galantamine (Reminyl XL ), Rivastigmine (Exelon ) and Memantine (Ebixa ) Donepezil (Aricept ), Galantamine (Reminyl XL ), Rivastigmine (Exelon ) and Memantine (Ebixa ) ESCA: For the treatment of Alzheimer s disease. SECONDARY CARE SECTION TO BE COMPLETED BY INITIATING DOCTOR

More information

Package leaflet: Information for the user

Package leaflet: Information for the user Package leaflet: Information for the user Infanrix -IPV+Hib (as logo) vaccine Powder and suspension for suspension for injection Diphtheria, tetanus, pertussis (acellular component), poliomyelitis (inactivated)

More information

Resource Document 6: Tetanus Immunization. I. Introduction

Resource Document 6: Tetanus Immunization. I. Introduction Resource Document 6: Tetanus Immunization I. Introduction Attention must be directed to adequate tetanus prophylaxis in the multiply injured patient, particularly if open-extremity trauma is present. The

More information

160S01105, Page 1 of 7. Human Hepatitis B Immunoglobulin, solution for intramuscular injection.

160S01105, Page 1 of 7. Human Hepatitis B Immunoglobulin, solution for intramuscular injection. 160S01105, Page 1 of 7 New Zealand Data Sheet Hepatitis B Immunoglobulin-VF NAME OF THE MEDICINE Human Hepatitis B Immunoglobulin, solution for intramuscular injection. DESCRIPTION Hepatitis B Immunoglobulin-VF

More information

11 MEDICATION MANAGEMENT

11 MEDICATION MANAGEMENT 1 11 MEDICATION MANAGEMENT OVERVIEW OF MEDICATION MANAGEMENT Depending on the size, structure and functions of the health facility, there may be a pharmacy with qualified pharmacists to dispense medication,

More information

PRODUCT INFORMATION. Pertussis Vaccine-Acellular Combined with Diphtheria and Tetanus Toxoids (Adsorbed)

PRODUCT INFORMATION. Pertussis Vaccine-Acellular Combined with Diphtheria and Tetanus Toxoids (Adsorbed) PRODUCT INFORMATION NAME OF THE DRUG ADACEL Pertussis Vaccine-Acellular Combined with Diphtheria and Tetanus Toxoids (Adsorbed) DESCRIPTION ADACEL is a sterile, uniform, cloudy, white suspension for injection.

More information

Immunity and how vaccines work

Immunity and how vaccines work 1 Introduction Immunity is the ability of the human body to protect itself from infectious disease. The defence mechanisms of the body are complex and include innate (non-specific, non-adaptive) mechanisms

More information

Frequently asked questions about whooping cough (pertussis)

Frequently asked questions about whooping cough (pertussis) Frequently asked questions about whooping cough (pertussis) About whooping cough What is whooping cough? Whooping cough is a highly contagious illness caused by bacteria. It mainly affects the respiratory

More information

After your child is immunised

After your child is immunised After your child is immunised What to expect after immunisations This leaflet tells you what reactions might occur after immunisation, and what to do about them. Only use this information as a guide. You

More information

SWINE FLU AND PREGNANCY

SWINE FLU AND PREGNANCY SWINE FLU AND PREGNANCY How to protect yourself and your baby This leaflet gives information about: Flu. Protect yourself and others. SWINE FLU AND PREGNANCY Contents What is swine flu? Swine flu is a

More information

Measles Mumps and Rubella Vaccine Having the MMR vaccine after having a baby

Measles Mumps and Rubella Vaccine Having the MMR vaccine after having a baby Measles Mumps and Rubella Vaccine Having the MMR vaccine after having a baby Information for parents Why am I being offered the MMR vaccine? Rubella can be serious for pregnant women due to the risks

More information

Naltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance

Naltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance Naltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance Introduction Indication/Licensing information: Naltrexone is licensed for use as an additional therapy, within

More information

Pertussis: halting the epidemic by protecting infants. 34 BPJ Issue 51

Pertussis: halting the epidemic by protecting infants. 34 BPJ Issue 51 Pertussis: halting the epidemic by protecting infants 34 BPJ Issue 51 Infants who have not yet completed the National Immunisation Schedule and children who are not immunised, or only partially immunised

More information

Humulin R (U500) insulin: Prescribing Guidance

Humulin R (U500) insulin: Prescribing Guidance Leeds Humulin R (U500) insulin: Prescribing Guidance Amber Drug Level 2 We have started your patient on Humulin R (U500) insulin for the treatment of diabetic patients with marked insulin resistance requiring

More information

POLICY DOCUMENT POLICY FOR PATIENT GROUP DIRECTIONS (PGD) Reference number Title: Policy for Patient Group Directions (PGD).

POLICY DOCUMENT POLICY FOR PATIENT GROUP DIRECTIONS (PGD) Reference number Title: Policy for Patient Group Directions (PGD). POLICY DOCUMENT POLICY FOR PATIENT GROUP DIRECTIONS (PGD) Reference number Title: Version number 1 Policy approved by Date of approval Policy for Patient Group Directions (PGD). Medicines Management Committee

More information

Suturing Policy for Nurses in Emergency Departments

Suturing Policy for Nurses in Emergency Departments This is an official Northern Trust policy and should not be edited in any way Suturing Policy for Nurses in Emergency Departments Reference Number: NHSCT/12/545 Target audience: Registered Nurses Sources

More information

Adverse Events Following Immunisation (AEFI) Noel McCarthy Thames Valley Public Health England Centre and Everybody

Adverse Events Following Immunisation (AEFI) Noel McCarthy Thames Valley Public Health England Centre and Everybody Adverse Events Following Immunisation (AEFI) Noel McCarthy Thames Valley Public Health England Centre and Everybody A fifteen year old with diabetes came for his MMR and was referred by the school nurse

More information